{"success":true,"data":{"pressRelease":{"id":"181222","rtpr_id":"nGNX3Yyd6Q-20261027","ticker":"ARDX","exchange":"NASDAQ","all_tickers":["ARDX"],"title":"Ardelyx, Inc. (NASDAQ:ARDX) SHAREHOLDER ALERT: Investors With Losses May Seek to Lead the Class Action in Ardelyx, Inc. Securities Lawsuit - Contact Portnoy Law Firm","author":"Globe Newswire","published_at":"2026-10-27T13:00:02.946Z","article_body":"LOS ANGELES, Oct. 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm notifies\ninvestors in Ardelyx, Inc. (NASDAQ: ARDX) that a securities class action\nlawsuit has been filed on behalf of shareholders who purchased or otherwise\nacquired Ardelyx common stock between February 12, 2026 and August 5, 2026,\ninclusive (the 'Class Period'). Find out if you qualify to recover your\nper-share losses by choosing to join the class action and submit your trade\ndetails\n(https://www.globenewswire.com/Tracker?data=o3fxsYUa6LiZh4GoxvVaJmAIAKl9mG1EnrQzmSqO0goP7hIY5S3SVTM4OuIDFOcqQgRFP8-xghZXsTtIE8YX0BI5s--lXBRUWg3jZkTZgva6OAokX3ny2JVrXe2wEriqeCTEukhPPGmXPHr37FyhgA==).\nInvestors who suffered financial losses have until November 16, 2026 to seek\nappointment as lead plaintiff. Shareholders should contact Lesley Portnoy via\ne-mail\n(https://www.globenewswire.com/Tracker?data=I2U5_JluCcMZxpJYdiYBTrrtJkMY65iOLiiohHBAyxwIwFK9c6Tlz3zxJjAlrWmZyLUCD0Sd4-oVTqNNOzv7mw==)\n(Lesley@portnoylaw.com or call (310) 692-8883) or visit\nhttp://portnoylaw.com/ardelyx-inc to learn more information and discuss their\nlegal rights.\n\nPlease visit our website\n(https://www.globenewswire.com/Tracker?data=zJYQpNCu0-gQYw76vjmyJlH40ndsKUnJHZbzYBpwoEDQOR-WZlSOiHglb8_WkO7GwePNsTZs52LyZBFOQ9X3efXV1DOMWdbzbNFZfaHd4K8=)\nfor more information on how to participate in this class action.\n\nIn addition to claims under Section 10(b) of the Exchange Act and Rule 10b-5,\nthe complaint asserts Section 20(a) control person liability against all four\nexecutive defendants. For investors, this mechanism establishes direct\naccountability: because these officers allegedly exercised authority over the\nmisleading representations, they can be held individually liable for\nshareholder losses rather than hiding behind the corporate entity.\n\nThe complaint details several bases for control person liability, asserting\nthat the defendants had:\n* Direct oversight over the reaffirmed long-term sales projections exceeding\n$1 billion for IBSRELA and $750 million for XPHOZAH.\n\n* Management responsibility for the commercial access strategy, including the\nArdelyxAssist patient services initiative and the expanded team of field\naccess managers.\n\n* Executed Sarbanes-Oxley Section 302 and Section 906 certifications as Chief\nExecutive Officer and Chief Financial Officer, verifying the accuracy of the\ncompany's SEC filings.\n\n* Direct access to non-public material facts regarding heightened prior\nauthorization demands and step-edit restrictions that hindered new patient\nadoption.\n\n* The authority and opportunity to prevent the publication of the false\nstatements or to issue corrective disclosures prior to their release.\n\n* Oversight during a Chief Financial Officer transition on November 4, 2025,\nwhich split SOX certification obligations between two different financial\nexecutives during the Class Period.\nFinally, the suit asserts that the contested disclosures represent\ngroup-published information stemming from the shared actions of the executive\ndefendants, and that their collective knowledge is attributable to Ardelyx\nunder legal agency doctrine.\n\nWHY PORTNOY LAW FIRM\n\nThe Portnoy Law Firm represents investors in complex securities class action\nlitigation and shareholder rights matters across the nation. Founded by Lesley\nPortnoy, the firm's attorneys have recovered billions of dollars for aggrieved\ninstitutional and retail investors. The firm leverages extensive legal\nexpertise and sophisticated financial forensic capabilities to hold public\ncorporations accountable for corporate wrongdoing and misrepresentation.\n\nLead Plaintiff Deadline: Investors who suffered losses on Ardelyx, Inc. stock\nduring the Class Period have until November 16, 2026 to seek appointment as\nlead plaintiff.\n\nFrequently Asked Questions About the Ardelyx Lawsuit\n\nQ: What is the Ardelyx lead plaintiff deadline?\nA: The deadline to apply for lead plaintiff appointment is November 16, 2026.\nThis deadline applies strictly to investors seeking to serve as lead plaintiff\nrepresenting the class. Class members who do not apply may still participate\nin any eventual financial recovery as absent class members without taking any\naction at this time.\n\nQ: How much did Ardelyx stock drop and on what dates?\nA: Following the after-hours disclosure on August 6, 2026, when Ardelyx\nannounced a reduction in its full-year 2026 IBSRELA revenue guidance due to\nincreased payer utilization-management processes and withdrew its long-term\nXPHOZAH revenue guidance, Ardelyx's common stock price fell from a closing\nprice of $4.87 per share on August 6, 2026, to $4.00 per share on August 7,\n2026, representing a single-day decline of about 18%.\n\nQ: What specific misstatements does the Ardelyx lawsuit allege?\nA: The lawsuit claims that Ardelyx and its executives misled investors by\nproviding highly confident revenue projections and long-term sales targets for\nits core drugs, XPHOZAH and IBSRELA, while hiding mounting business hurdles.\nSpecifically, the complaint alleges that the company downplayed growing\ninsurance and payer-related barriers—such as stricter prior authorization\nrules and step-edit requirements—that were slowing down new patient starts\nand delaying prescription fulfillment. When these pressures ultimately forced\nmanagement to cut its 2026 sales forecast for IBSRELA and scrap its long-term\ngoals for XPHOZAH, investors suffered significant financial losses.\n\nQ: What do Ardelyx investors need to do right now?\nA: Investors who purchased ARDX common stock during the Class Period (February\n12, 2026 through August 5, 2026) should gather their trade confirmation slips\nor brokerage transaction logs showing purchase dates, number of shares, and\nprices paid. You may submit your trade details to Portnoy Law Firm here\n(https://www.globenewswire.com/Tracker?data=bwemq0PVh3Zpoent6Zfwgq1JDicKGLfWr1R2EHq8yOzS5d5qVzjACCihlRgrK9UtrHYlku8MJHMBRNGM7sh8DdNQUmDdedJ8P1Wt0XFn7jtQ2_RV0Ufn44BaXqns-PHzcZhOIu_NmSt0oDoulORxyY6XWhJ6Vt44-gqCL1IEQaQ=)\nfor a free, no-obligation evaluation of your potential loss recovery. No\nimmediate legal action is required to remain an eligible absent class member.\n\nQ: What is a lead plaintiff and why does it matter?\nA: A lead plaintiff is a court-appointed class member who acts on behalf of\nall other class members in directing the litigation. The lead plaintiff is\ntypically the investor or group of investors that makes a motion with the\nlargest financial interest in the relief sought. While serving as lead\nplaintiff does not increase an investor's individual financial recovery\ncompared to other class members, it gives the investor direct authority to\nselect lead counsel and oversee the prosecution of the lawsuit.\n\nQ: Does the lead plaintiff receive any type of compensation?\nA: Yes, in many cases, Courts award the lead plaintiff an additional amount of\nmoney to compensate the lead plaintiff for their participation in the case.\n\nQ: Does it cost anything to participate in this case as a lead plaintiff?\nA: A lead plaintiff does not pay any fees or expenses out of pocket. Our firm\nworks on a contingency basis, and will collect any fees or expenses directly\nfrom a future recovery.\n\nQ: What if I already sold my Ardelyx shares -- can I still recover losses?\nA: Yes. Eligibility to participate in a securities class action recovery\ndepends on whether you purchased or acquired ARDX common stock during the\nClass Period (February 12, 2026 to August 5, 2026) and suffered an economic\nloss. Investors who sold their shares prior to or after the public disclosures\nmay still be eligible to recover damages based on the artificial inflation\npresent in the stock at the time of purchase.\n\nQ: How long will the Ardelyx lawsuit take to resolve?\nA: Securities class action lawsuits typically take between two and four years\nfrom initial filing to full resolution. The exact timeline depends on court\nscheduling, motion practice (such as motions to dismiss), pre-trial discovery,\nand potential settlement negotiations or trial proceedings.\n\nQ: Can I choose a different law firm to represent me?\nA: Yes. Investors have the absolute right to retain any legal counsel of their\nchoice. When multiple class action complaints are filed, the court will\nconsolidate the actions and appoint a lead plaintiff and lead counsel. You may\nchoose to be represented by Portnoy Law Firm, retain separate counsel, or\nremain an absent class member represented by court-appointed lead counsel.\n\nCONTACT INFORMATION\n\nPortnoy Law Firm\nLesley Portnoy, Esq.\nEmail: lesley@portnoylaw.com / info@portnoylaw.com\nTelephone: (310) 692-8883\n\nAttorney Advertising. Prior results do not guarantee a similar outcome.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/ea0dd9c0-6e41-4d5a-ad27-b277677af6df)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX3Yyd6Q-20261027","title":"Ardelyx, Inc. (NASDAQ:ARDX) SHAREHOLDER ALERT: Investors With Losses May Seek to Lead the Class Action in Ardelyx, Inc. Securities Lawsuit - Contact Portnoy Law Firm","author":"Globe Newswire","ticker":"ARDX","created":"2026-10-27T13:00:02.946Z","tickers":["ARDX"],"exchange":"NASDAQ","article_body":"LOS ANGELES, Oct. 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm notifies\ninvestors in Ardelyx, Inc. (NASDAQ: ARDX) that a securities class action\nlawsuit has been filed on behalf of shareholders who purchased or otherwise\nacquired Ardelyx common stock between February 12, 2026 and August 5, 2026,\ninclusive (the 'Class Period'). Find out if you qualify to recover your\nper-share losses by choosing to join the class action and submit your trade\ndetails\n(https://www.globenewswire.com/Tracker?data=o3fxsYUa6LiZh4GoxvVaJmAIAKl9mG1EnrQzmSqO0goP7hIY5S3SVTM4OuIDFOcqQgRFP8-xghZXsTtIE8YX0BI5s--lXBRUWg3jZkTZgva6OAokX3ny2JVrXe2wEriqeCTEukhPPGmXPHr37FyhgA==).\nInvestors who suffered financial losses have until November 16, 2026 to seek\nappointment as lead plaintiff. Shareholders should contact Lesley Portnoy via\ne-mail\n(https://www.globenewswire.com/Tracker?data=I2U5_JluCcMZxpJYdiYBTrrtJkMY65iOLiiohHBAyxwIwFK9c6Tlz3zxJjAlrWmZyLUCD0Sd4-oVTqNNOzv7mw==)\n(Lesley@portnoylaw.com or call (310) 692-8883) or visit\nhttp://portnoylaw.com/ardelyx-inc to learn more information and discuss their\nlegal rights.\n\nPlease visit our website\n(https://www.globenewswire.com/Tracker?data=zJYQpNCu0-gQYw76vjmyJlH40ndsKUnJHZbzYBpwoEDQOR-WZlSOiHglb8_WkO7GwePNsTZs52LyZBFOQ9X3efXV1DOMWdbzbNFZfaHd4K8=)\nfor more information on how to participate in this class action.\n\nIn addition to claims under Section 10(b) of the Exchange Act and Rule 10b-5,\nthe complaint asserts Section 20(a) control person liability against all four\nexecutive defendants. For investors, this mechanism establishes direct\naccountability: because these officers allegedly exercised authority over the\nmisleading representations, they can be held individually liable for\nshareholder losses rather than hiding behind the corporate entity.\n\nThe complaint details several bases for control person liability, asserting\nthat the defendants had:\n* Direct oversight over the reaffirmed long-term sales projections exceeding\n$1 billion for IBSRELA and $750 million for XPHOZAH.\n\n* Management responsibility for the commercial access strategy, including the\nArdelyxAssist patient services initiative and the expanded team of field\naccess managers.\n\n* Executed Sarbanes-Oxley Section 302 and Section 906 certifications as Chief\nExecutive Officer and Chief Financial Officer, verifying the accuracy of the\ncompany's SEC filings.\n\n* Direct access to non-public material facts regarding heightened prior\nauthorization demands and step-edit restrictions that hindered new patient\nadoption.\n\n* The authority and opportunity to prevent the publication of the false\nstatements or to issue corrective disclosures prior to their release.\n\n* Oversight during a Chief Financial Officer transition on November 4, 2025,\nwhich split SOX certification obligations between two different financial\nexecutives during the Class Period.\nFinally, the suit asserts that the contested disclosures represent\ngroup-published information stemming from the shared actions of the executive\ndefendants, and that their collective knowledge is attributable to Ardelyx\nunder legal agency doctrine.\n\nWHY PORTNOY LAW FIRM\n\nThe Portnoy Law Firm represents investors in complex securities class action\nlitigation and shareholder rights matters across the nation. Founded by Lesley\nPortnoy, the firm's attorneys have recovered billions of dollars for aggrieved\ninstitutional and retail investors. The firm leverages extensive legal\nexpertise and sophisticated financial forensic capabilities to hold public\ncorporations accountable for corporate wrongdoing and misrepresentation.\n\nLead Plaintiff Deadline: Investors who suffered losses on Ardelyx, Inc. stock\nduring the Class Period have until November 16, 2026 to seek appointment as\nlead plaintiff.\n\nFrequently Asked Questions About the Ardelyx Lawsuit\n\nQ: What is the Ardelyx lead plaintiff deadline?\nA: The deadline to apply for lead plaintiff appointment is November 16, 2026.\nThis deadline applies strictly to investors seeking to serve as lead plaintiff\nrepresenting the class. Class members who do not apply may still participate\nin any eventual financial recovery as absent class members without taking any\naction at this time.\n\nQ: How much did Ardelyx stock drop and on what dates?\nA: Following the after-hours disclosure on August 6, 2026, when Ardelyx\nannounced a reduction in its full-year 2026 IBSRELA revenue guidance due to\nincreased payer utilization-management processes and withdrew its long-term\nXPHOZAH revenue guidance, Ardelyx's common stock price fell from a closing\nprice of $4.87 per share on August 6, 2026, to $4.00 per share on August 7,\n2026, representing a single-day decline of about 18%.\n\nQ: What specific misstatements does the Ardelyx lawsuit allege?\nA: The lawsuit claims that Ardelyx and its executives misled investors by\nproviding highly confident revenue projections and long-term sales targets for\nits core drugs, XPHOZAH and IBSRELA, while hiding mounting business hurdles.\nSpecifically, the complaint alleges that the company downplayed growing\ninsurance and payer-related barriers—such as stricter prior authorization\nrules and step-edit requirements—that were slowing down new patient starts\nand delaying prescription fulfillment. When these pressures ultimately forced\nmanagement to cut its 2026 sales forecast for IBSRELA and scrap its long-term\ngoals for XPHOZAH, investors suffered significant financial losses.\n\nQ: What do Ardelyx investors need to do right now?\nA: Investors who purchased ARDX common stock during the Class Period (February\n12, 2026 through August 5, 2026) should gather their trade confirmation slips\nor brokerage transaction logs showing purchase dates, number of shares, and\nprices paid. You may submit your trade details to Portnoy Law Firm here\n(https://www.globenewswire.com/Tracker?data=bwemq0PVh3Zpoent6Zfwgq1JDicKGLfWr1R2EHq8yOzS5d5qVzjACCihlRgrK9UtrHYlku8MJHMBRNGM7sh8DdNQUmDdedJ8P1Wt0XFn7jtQ2_RV0Ufn44BaXqns-PHzcZhOIu_NmSt0oDoulORxyY6XWhJ6Vt44-gqCL1IEQaQ=)\nfor a free, no-obligation evaluation of your potential loss recovery. No\nimmediate legal action is required to remain an eligible absent class member.\n\nQ: What is a lead plaintiff and why does it matter?\nA: A lead plaintiff is a court-appointed class member who acts on behalf of\nall other class members in directing the litigation. The lead plaintiff is\ntypically the investor or group of investors that makes a motion with the\nlargest financial interest in the relief sought. While serving as lead\nplaintiff does not increase an investor's individual financial recovery\ncompared to other class members, it gives the investor direct authority to\nselect lead counsel and oversee the prosecution of the lawsuit.\n\nQ: Does the lead plaintiff receive any type of compensation?\nA: Yes, in many cases, Courts award the lead plaintiff an additional amount of\nmoney to compensate the lead plaintiff for their participation in the case.\n\nQ: Does it cost anything to participate in this case as a lead plaintiff?\nA: A lead plaintiff does not pay any fees or expenses out of pocket. Our firm\nworks on a contingency basis, and will collect any fees or expenses directly\nfrom a future recovery.\n\nQ: What if I already sold my Ardelyx shares -- can I still recover losses?\nA: Yes. Eligibility to participate in a securities class action recovery\ndepends on whether you purchased or acquired ARDX common stock during the\nClass Period (February 12, 2026 to August 5, 2026) and suffered an economic\nloss. Investors who sold their shares prior to or after the public disclosures\nmay still be eligible to recover damages based on the artificial inflation\npresent in the stock at the time of purchase.\n\nQ: How long will the Ardelyx lawsuit take to resolve?\nA: Securities class action lawsuits typically take between two and four years\nfrom initial filing to full resolution. The exact timeline depends on court\nscheduling, motion practice (such as motions to dismiss), pre-trial discovery,\nand potential settlement negotiations or trial proceedings.\n\nQ: Can I choose a different law firm to represent me?\nA: Yes. Investors have the absolute right to retain any legal counsel of their\nchoice. When multiple class action complaints are filed, the court will\nconsolidate the actions and appoint a lead plaintiff and lead counsel. You may\nchoose to be represented by Portnoy Law Firm, retain separate counsel, or\nremain an absent class member represented by court-appointed lead counsel.\n\nCONTACT INFORMATION\n\nPortnoy Law Firm\nLesley Portnoy, Esq.\nEmail: lesley@portnoylaw.com / info@portnoylaw.com\nTelephone: (310) 692-8883\n\nAttorney Advertising. Prior results do not guarantee a similar outcome.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/ea0dd9c0-6e41-4d5a-ad27-b277677af6df)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-27T13:00:03.004357236Z","server_sent_at_ms":1793106003004},"received_at":"2026-10-27T13:00:03.072Z","source_url":null},"analysis":{"id":"169032","press_release_id":"181222","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["ongoing securities class action alleging misleading revenue projections for IBSRELA and XPHOZAH","Section 20(a) control-person claims name all four executive defendants","complaint cites SOX certification risk tied to November 2025 CFO transition"],"eventType":"legal_litigation","narrative":"Portnoy Law Firm announced a securities class action against Ardelyx covering shareholders who bought ARDX between February 12, 2026 and August 5, 2026, with a lead plaintiff deadline of November 16, 2026.\n\nThe suit alleges the company and four executives downplayed payer barriers — prior authorizations and step-edits — before cutting full-year IBSRELA guidance and withdrawing XPHOZAH long-term guidance on August 6, 2026, sending the stock from $4.87 to $4.00, an ~18% one-day drop.\n\nThis is law-firm solicitation marketing rather than a new company disclosure; no court certification or settlement is announced.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation referencing previously disclosed guidance cut — suppress."},"keyFigures":{"customDimensions":{"stock_close_aug_6_2026":4.87,"stock_close_aug_7_2026":4,"lead_plaintiff_deadline":"November 16, 2026","single_day_stock_decline_pct":"about 18%"}},"namedEntities":{"people":[{"name":"Lesley Portnoy","role":"Founder, Portnoy Law Firm"}],"products":["IBSRELA","XPHOZAH"],"companies":[{"name":"Ardelyx, Inc.","ticker":"ARDX","relationship":"target of securities class action"},{"name":"Portnoy Law Firm","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$1 billion","context":"long-term IBSRELA sales projection cited in complaint"},{"amount":"$750 million","context":"long-term XPHOZAH revenue projection cited in complaint"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation by Portnoy Law Firm for a previously disclosed securities class action; no new issuer disclosure, certified class, or settlement. The release's purpose is lead-plaintiff recruitment."},"tickerRelevance":{"others":[],"primary":"ARDX"},"globalImportance":15,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingEvent":"previously disclosed guidance cut and 18% stock drop"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Portnoy Law Firm announced a securities class action against Ardelyx covering shareholders who bought ARDX between February 12, 2026 and August 5, 2026, with a lead plaintiff deadline of November 16, 2026.\n\nThe suit alleges the company and four executives downplayed payer barriers — prior authorizations and step-edits — before cutting full-year IBSRELA guidance and withdrawing XPHOZAH long-term guidance on August 6, 2026, sending the stock from $4.87 to $4.00, an ~18% one-day drop.\n\nThis is law-firm solicitation marketing rather than a new company disclosure; no court certification or settlement is announced.","key_figures":{"customDimensions":{"stock_close_aug_6_2026":4.87,"stock_close_aug_7_2026":4,"lead_plaintiff_deadline":"November 16, 2026","single_day_stock_decline_pct":"about 18%"}},"named_entities":{"people":[{"name":"Lesley Portnoy","role":"Founder, Portnoy Law Firm"}],"products":["IBSRELA","XPHOZAH"],"companies":[{"name":"Ardelyx, Inc.","ticker":"ARDX","relationship":"target of securities class action"},{"name":"Portnoy Law Firm","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$1 billion","context":"long-term IBSRELA sales projection cited in complaint"},{"amount":"$750 million","context":"long-term XPHOZAH revenue projection cited in complaint"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-27T13:00:17.820Z","global_importance":15,"audience_relevance":12,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingEvent":"previously disclosed guidance cut and 18% stock drop"}},"durationMs":5548,"modelName":"glm-5.3-flashx"}}